Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.3300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 3.3300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 8530 | 3.305 |
| 09:34 ET | 917 | 3.3 |
| 09:36 ET | 2509 | 3.32 |
| 09:38 ET | 4610 | 3.28 |
| 09:39 ET | 1100 | 3.3 |
| 09:41 ET | 200 | 3.3 |
| 09:43 ET | 3675 | 3.26 |
| 09:45 ET | 200 | 3.275 |
| 09:48 ET | 4248 | 3.27 |
| 09:50 ET | 600 | 3.27 |
| 09:52 ET | 1270 | 3.275 |
| 09:54 ET | 6746 | 3.3 |
| 09:56 ET | 600 | 3.2801 |
| 09:57 ET | 1800 | 3.26 |
| 09:59 ET | 200 | 3.28 |
| 10:01 ET | 600 | 3.29 |
| 10:03 ET | 1978 | 3.29 |
| 10:06 ET | 1391 | 3.3 |
| 10:08 ET | 641 | 3.3 |
| 10:10 ET | 391 | 3.3 |
| 10:12 ET | 703 | 3.3 |
| 10:14 ET | 274 | 3.3 |
| 10:15 ET | 315 | 3.3 |
| 10:17 ET | 391 | 3.3096 |
| 10:19 ET | 1894 | 3.3 |
| 10:21 ET | 9290 | 3.305 |
| 10:24 ET | 1434 | 3.3069 |
| 10:26 ET | 515 | 3.31 |
| 10:28 ET | 376 | 3.31 |
| 10:30 ET | 215 | 3.31 |
| 10:32 ET | 518 | 3.309 |
| 10:33 ET | 1179 | 3.31 |
| 10:37 ET | 100 | 3.31 |
| 10:42 ET | 352 | 3.315 |
| 10:48 ET | 461 | 3.315 |
| 10:50 ET | 100 | 3.315 |
| 10:53 ET | 2036 | 3.31 |
| 10:55 ET | 100 | 3.305 |
| 11:00 ET | 422 | 3.305 |
| 11:09 ET | 3320 | 3.3 |
| 11:11 ET | 100 | 3.31 |
| 11:22 ET | 1753 | 3.3 |
| 11:24 ET | 1204 | 3.3 |
| 11:26 ET | 100 | 3.3 |
| 11:27 ET | 1572 | 3.29 |
| 11:31 ET | 2500 | 3.3 |
| 11:33 ET | 3535 | 3.31 |
| 11:44 ET | 2894 | 3.32 |
| 11:45 ET | 300 | 3.32 |
| 11:47 ET | 100 | 3.32 |
| 11:49 ET | 220 | 3.32 |
| 11:51 ET | 3628 | 3.34 |
| 11:58 ET | 172 | 3.35 |
| 12:03 ET | 407 | 3.3531 |
| 12:14 ET | 100 | 3.36 |
| 12:20 ET | 130 | 3.365 |
| 12:21 ET | 500 | 3.365 |
| 12:23 ET | 200 | 3.37 |
| 12:27 ET | 265 | 3.36 |
| 12:30 ET | 300 | 3.36 |
| 12:32 ET | 1483 | 3.3899 |
| 12:34 ET | 914 | 3.3701 |
| 12:38 ET | 100 | 3.375 |
| 12:41 ET | 666 | 3.3784 |
| 12:43 ET | 826 | 3.374 |
| 12:52 ET | 100 | 3.38 |
| 12:54 ET | 148 | 3.3709 |
| 12:56 ET | 357 | 3.36 |
| 12:57 ET | 200 | 3.36 |
| 12:59 ET | 1100 | 3.35 |
| 01:08 ET | 880 | 3.35 |
| 01:12 ET | 280 | 3.345 |
| 01:15 ET | 149 | 3.34 |
| 01:19 ET | 100 | 3.35 |
| 01:28 ET | 3374 | 3.37 |
| 01:30 ET | 100 | 3.365 |
| 01:33 ET | 108 | 3.365 |
| 01:35 ET | 100 | 3.365 |
| 01:39 ET | 1103 | 3.37 |
| 01:46 ET | 100 | 3.365 |
| 01:48 ET | 200 | 3.365 |
| 01:50 ET | 100 | 3.365 |
| 01:51 ET | 5363 | 3.3794 |
| 01:57 ET | 600 | 3.37 |
| 02:02 ET | 542 | 3.37 |
| 02:04 ET | 878 | 3.38 |
| 02:08 ET | 399 | 3.38 |
| 02:13 ET | 100 | 3.385 |
| 02:15 ET | 1200 | 3.39 |
| 02:18 ET | 100 | 3.385 |
| 02:20 ET | 200 | 3.385 |
| 02:24 ET | 160 | 3.3898 |
| 02:27 ET | 600 | 3.38 |
| 02:29 ET | 200 | 3.37 |
| 02:33 ET | 200 | 3.36 |
| 02:38 ET | 3556 | 3.36 |
| 02:40 ET | 2453 | 3.36 |
| 02:44 ET | 100 | 3.355 |
| 02:45 ET | 100 | 3.355 |
| 02:47 ET | 600 | 3.35 |
| 02:49 ET | 200 | 3.345 |
| 02:51 ET | 797 | 3.34 |
| 02:58 ET | 600 | 3.34 |
| 03:02 ET | 226 | 3.33 |
| 03:07 ET | 100 | 3.33 |
| 03:09 ET | 300 | 3.33 |
| 03:12 ET | 100 | 3.32 |
| 03:14 ET | 100 | 3.325 |
| 03:16 ET | 1285 | 3.335 |
| 03:18 ET | 300 | 3.34 |
| 03:20 ET | 300 | 3.335 |
| 03:21 ET | 200 | 3.335 |
| 03:23 ET | 417 | 3.335 |
| 03:25 ET | 1955 | 3.345 |
| 03:27 ET | 100 | 3.35 |
| 03:30 ET | 324 | 3.345 |
| 03:32 ET | 767 | 3.35 |
| 03:34 ET | 663 | 3.35 |
| 03:36 ET | 814 | 3.34 |
| 03:39 ET | 436 | 3.335 |
| 03:41 ET | 583 | 3.33 |
| 03:43 ET | 2423 | 3.325 |
| 03:45 ET | 1285 | 3.33 |
| 03:48 ET | 626 | 3.33 |
| 03:50 ET | 300 | 3.34 |
| 03:52 ET | 950 | 3.335 |
| 03:54 ET | 7021 | 3.335 |
| 03:56 ET | 3172 | 3.32 |
| 03:57 ET | 1431 | 3.33 |
| 03:59 ET | 8608 | 3.33 |
Yesterday
Jun 20, 2024
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable, from 7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
7:00AM ET on Thursday Jun 20, 2024 by Dow Jones
Jun 13, 2024
Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below, from 11:02AM ET on Thursday Jun 13, 2024 by Dow Jones
11:02AM ET on Thursday Jun 13, 2024 by Dow JonesAldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease, from 7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
7:00AM ET on Thursday Jun 13, 2024 by Dow Jones
Jun 12, 2024
Aldeyra Therapeutics to Host Investor Roundtable Q&A, from 7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 195.5M | -6.6x | --- |
Acrivon Therapeutics Inc | 193.3M | -2.1x | --- |
Biomea Fusion Inc | 199.5M | -1.5x | --- |
Greenwich Lifesciences Inc | 199.6M | -21.4x | --- |
Design Therapeutics Inc | 189.8M | -3.2x | --- |
Pyxis Oncology Inc | 187.9M | -2.2x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $195.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -6.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
